Novo Nordisk CEO: Future obesity market size is difficult to assess
The Danish drugmaker wants to generate ”more than DKK 25bn” in its obesity business in 2025 – but CEO Lars Fruergaard Jørgensen declines to come with personal predictions.
by christopher due karlsson, translated by daniel pedersen
Novo Nordisk Chief Executive Lars Fruergaard Jørgensen does not want to make any large-scale predictions about the sales potential of the obesity market to Danish business daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
